Skip to main content

Do Proton Pump Inhibitors Increase Risk for Dementia?

Case: Ms. P is a 76 year old lady with a past medical history of GERD, osteoporosis status post right hip fracture, C. diff infection in 2011, uterine fibroids status post TAH-BSO, who comes in for a follow-up visit. Her medications include omeprazole 40 mg daily, vitamin D 800 IU daily, alendronate 70 mg weekly. Physical exam is unremarkable, except for BMI of 18. During medication reconciliation, she asks, “I heard that my omeprazole can cause dementia…”

I recalled the recent NY Times article about heartburn drugs related to increased risk of dementia and wondered if that could be possible. I told Ms. P, “I will look into that and let you know if you need to be concerned about that.”

The question was: In older patients, is the exposure to proton pump inhibitor (PPI) medications as compared to no exposure associated with increased risk of dementia? In order to answer this question, I performed a search for “PPI and dementia risk” in PubMed. I found two recent studies to review.


In 2015, Haenish and colleagues published the results of the German Study on Aging, Cognition and Dementia in elderly primary care patients (AgeCoDe). This was a longitudinal, multicenter cohort study involving 3,327 community-dwelling persons aged 75 years or older without any dementia at baseline. There were four 1.5 year follow up points with an overall follow up time of 6 years. Using time-dependent Cox regression, the authors found that PPI users had a significantly increased risk of any dementia [Hazard ratio (HR) 1.38, 95% confidence interval (CI) 1.04-1.83] and Alzheimer's disease (HR 1.44, 95% CI 1.01-2.06) compared with nonusers. This risk persisted after adjusting for potential confounding factors: age, sex, education, ApoE4 allele, polypharmacy, depression, DM, ischemic HD and stroke.

In 2016, the same group published results of a larger prospective cohort study using routine claims data from the largest mandatory public health insurer in Germany. The study included 73,679 elderly patients, aged 75 years or older free of dementia at baseline that were followed for 7 years. After controlling for confounding factors (i.e. age, sex, polypharmacy, stroke, depression, ischemic HD, DM), the study found an association between regular PPI use and incident dementia compared to PPI non-users [hazard ratio, 1.44 [95% CI, 1.36-1.52]; P < .001]. Interestingly, the HR for occasional PPI users over non-users was 1.16.

These studies show a potential relationship between PPI use and increased risk of new dementia. However, there are several caveats. Cohort designs can only demonstrate an association, not causation. The authors’ conclusion that “the avoidance of PPI medication may prevent the development of dementia” must be interpreted with caution. This one is, at best, a weak association, with a wide confidence interval (in the first study). A randomized, placebo-controlled study would need to be performed to show a causal relationship. A dose–response relationship, if reliably demonstrated, might strengthen the association. It is also interesting to note that the prevalence of PPI use in Germany is about four percent, whereas it is higher in the US, especially given it’s availability over the counter.

It is fair to say however, that unnecessary, long-term use of any medications – including PPIs – should be avoided. Until we have further information, prescribers should remain judicious in the use of PPIs and look for inappropriate prescribing, especially in geriatric patients who are at risk for polypharmacy and the negative implications of medication over-prescription.

By Eugenia Shmidt, MD, GI Fellow at Icahn School of Medicine at Mount Sinai, New York


References:
1. Haenisch B, von Holt K, Wiese B, Prokein J, Lange C, Ernst A, Brettschneider C, König HH, Werle J, Weyerer S, Luppa M, Riedel-Heller SG, Fuchs A, Pentzek M, Weeg D, Bickel H, Broich K, Jessen F, Maier W, Scherer M. Risk of dementia in elderly patients with the use of proton pump inhibitors. Eur Arch Psychiatry Clin Neurosci. 2015 Aug;265(5):419-28.
2. Gomm W, von Holt K, Thomé F1, Broich K, Maier W, Fink A4, Doblhammer G, Haenisch B. Association of Proton Pump Inhibitors With Risk of Dementia: A Pharmacoepidemiological Claims Data Analysis. AMA Neurol. 2016 Apr 1;73(4):410-6.
Photo courtesy: Will Culpepper

This post is part of the #GeriCases series, in which we discuss a clinical case in geriatrics and palliative medicine and the attempt to provide patient-centered care with the use of best available evidence.
Ravishankar Ramaswamy, MD
@RavRamaswamy
Section Editor, #GeriCases

Comments

Anonymous said…
I wondered too... EXCELLENT response! Thanks.
Certainly a fantastic piece of work ... It has relevant information. Thanks for posting this.

Popular posts from this blog

The Future of Palliative Care: A Podcast with Diane Meier

There are few names more closely associated with palliative care than Diane Meier.  She is an international leader of palliative care, a MacArthur "genius" awardee, and amongst many other leadership roles, the CEO of the Center to Advance Palliative Care (CAPC).  We were lucky enough to snag Diane for our podcast to talk about everything we always wanted to ask her, including:
What keeps her up at night?Does palliative care need a national strategy and if so why and what would it look like?The history of CAPC and the leadership centersAdvice that she has for graduating fellows who want to continue to move palliative care forward as they start their new careersWhat she imagines palliative care will look like in 10 or 15 years?What is the biggest threat facing palliative care? So take a listen and if you want to dive a little deeper, here are two articles that we discussed during the podcast:
A National Strategy For Palliative Care. Health Affairs 2017Palliative Care Leadership…

Advance Care Planning before Major Surgery: A Podcast with Vicky Tang

This week's podcast is all about the intersection of geriatrics, palliative care, advanced care planning and surgery with our guest Dr. Vicky Tang.  Vicky is an assistant professor and researcher here at UCSF.  We talk about her local and national efforts focused on this intersection, including:
Her JAMA Surgery article that showed 3 out of 4 older adults undergoing high risk surgery had no advance care planning (ACP) documentation. Prehab clinics and how ACP fits into these clinicsThe Geriatric Surgery Verification Quality Improvement Program whose goal is to set the standards for geriatric surgical care including ACP discussions prior to surgeryHow frailty fits in and how to assess it (including this paper from JAGS on the value of the chair raise test) So take a listen and check out some of those links.  For those who want to take a deeper dive into how GeriPal and surgery fit together, check out these other podcasts: Zara Cooper on Trauma Surgery, Geriatrics, and Palliative Car…

Psychedelics: Podcast with Ira Byock

In this week's podcast, we talk with Dr. Ira Byock, a leading palliative care physician, author, and public advocate for improving care through the end of life.

Ira Byock wrote a provocative and compelling paper in the Journal of Pain and Symptom Management titled, "Taking Psychedelics Seriously."

In this podcast we challenge Ira Byock about the use of psychedelics for patients with serious and life-limiting illness.   Guest host Josh Biddle (UCSF Palliative care fellow) asks, "Should clinicians who prescribe psychedelics try them first to understand what their patient's are going through?" The answer is "yes" -- read or listen on for more!

While you're reading, I'll just go over and lick this toad.

-@AlexSmithMD





You can also find us on Youtube!



Listen to GeriPal Podcasts on:
iTunes Google Play MusicSoundcloudStitcher
Transcript
Eric: Welcome to the GeriPal Podcast. This is Eric Widera.

Alex: This is Alex Smith.

Eric: Alex, I spy someone in our …